Abstract:Objective: To investigate the serum levels of inflammatory cytokines and the correlations with Parkinson’s disease (PD) clinical symptoms. Methods: Serum levels of the cytokines, including IL-6, IL-8, and TNF-α, were measured in 273 PD patients and 91 healthy controls (HCs). The clinical manifestations of PD were assessed with nine different scales to evaluate the cognitive function, non-motor symptoms, motor symptoms, and disease severity. The differences in these inflammatory indicators were examined between PD patients and HCs, and the correlations of these inflammatory indicators with clinical variables were analyzed in PD patients. Results: Serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in PD patients were higher than those in HCs, but serum interleukin-8 (IL-8) level was not significantly different from that in HCs. In PD patients, serum IL-6 level was positively correlated with age of onset, the Hamilton Depression Scale (HAMD), and the Non-Motor Symptom Scale (NMSS), UPDRS part I, part II, and part III, but it was inversely correlated with the Frontal Assessment Battery (FAB) and the Montreal Cognitive Assessment (MoCA) scores. Serum TNF-α level was positively correlated with age of onset and H&Y stage in PD patients (p = .037), but negatively correlated with FAB scores in PD patients (p = .010). However, no associations were found between all the clinical variables and the serum IL-8 level. The forward binary logistic regression model revealed that serum IL-6 level was associated with MoCA (p = .023) and UPDRS I scores (p = .023), but no associations was found with the remaining factors. The ROC curve of TNF-α for the diagnosis of PD showed the area under the curve (AUC) was .719 (p < .05, 95% CI: .655–.784), and the critical value of TNF-α was 5.380 pg/ml, with a diagnostic sensitivity of 76.0% and a specificity of 59.3%. Conclusion: Our results suggest increased serum levels of IL-6 and TNF-α in PD, we further found that IL-6 level was associated with non-motor symptoms and cognitive dysfunction, and IL-6 may play a role in the pathophysiology of non-motor symptoms in PD. At the same time, we also propose that TNF-α has a good diagnostic value for PD despite its irrelevance to clinical symptoms.

Changes of IL-2,IL-6 and IL-10 of Parkionson's Disease Patients

Changes of T lymphocyte subgroups in peripheral blood of Parkionson's disease patients

Changes of humoral immune function in patients with Parkinson disease

Study of IL-2 secretion from peripheral blood mononuclear cells of Parkinson's disease patients

Cytokine and Chemokine Map of Peripheral Specific Immune Cell Subsets in Parkinson's Disease

Th1/Th2 Type Cytokine Gene Expression in the Peripheral Blood of Patients with Parkinson Disease

Serum Inflammatory Cytokines Levels and the Correlation Analyses in Parkinson’s Disease

Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.

Study on changes of the levels of EGF, BDNF in serum and their relations with cognitive impairment in patients with Parkinson's disease

Cytokine and chemokine map of peripheral specific immune cell subsets in Parkinson’s disease

Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein As Important Markers of Parkinson's Disease Severity

Peripheral Biomarkers of Parkinson’s Disease and Its Correlation with Clinical Symptoms: a Case-Control Study

T Lymphocyte Subgroups and Erythrocyte Immune Function in Parkinson Disease Patients

The Parkinson patients serum levels of TNF-α,sTNFR1,sTNFR2 detection and clinical significance

Correlation Between Serum RANTES Levels and the Severity of Parkinson's Disease.

Changes of Pro-and Anti-Inflammatory Cytokines in Serum and Cerebrospinal Fluid of Patients with Different Kinds of Dementias

Clinical Correlation of Peripheral CD4+‑cell Sub‑sets, Their Imbalance and Parkinson's Disease.

Evidence for Peripheral Immune Activation in Parkinson's Disease.

Parkinson's Disease Peripheral Immune Biomarker Profile: a Multicentre, Cross-Sectional and Longitudinal Study

Peripheral Humoral Immune Response Is Associated With the Non-motor Symptoms of Parkinson’s Disease